tbuckley/cabot-search huggingface dataset:
Table of Contents
Authors: Nicholas Chun, Christina Wyatt, John He, Reiko Inagi, Yu Ishimoto, Ming Jao, John Montford, Seth Furgeson, Nina Boiko, Jonathan Berman, Elena Mironova, James Stockand, Joshua Thurman, Jennifer Laskowski, Girish Nadkarni, Steven Coca, Ségolène Aymé, Detlef Bockenhauer, Simon Day, Olivier Devuyst, Lisa Guay-Woodford, Julie Ingelfinger, Jon Klein, V Knoers, Ronald Perrone, Julia Roberts, Franz Schaefer, Vicente Torres, Michael Cheung, David Wheeler, Wolfgang Winkelmayer, James Tomlinson
Journal: Kidney International (2017)
Meningealleukemia. Two simple methods for rapid detection of malignant cells in spinal fluid
Authors: R. T. Skeel
Journal: JAMA (1968)

The syndrome of meningeal leukemia is one of the major complications of acute leukemia.<sup>1,2</sup>The manifestations of the clinical syndrome include headache, nausea, vomiting, eye signs, cranial nerve palsies, and lethargy, and may be associated with increased intracranial pressure. The observation that cerebrospinal fluid (CSF) pleocytosis is almost always associated with the clinical syndrome has shifted the emphasis in the criteria for diagnosis from dependence on clinical signs and symptoms to a greater reliance on laboratory findings.<sup>3,4</sup>More recent studies further demonstrate that the CSF pleocytosis may precede the symptoms. In the review of cases reported by Nies et al,<sup>3</sup>the diagnosis of meningeal leukemia was said to be established by the presence of ten or more mononuclear cells per cubic millimeter in the spinal fluid. Judged by this criterion, of 38 cases of meningeal leukemia, 14 had no presenting signs or symptoms at the time of
TH1/TH17 profiles in crohn's disease: a cross sectional single centre study in postoperative crohn's disease
Authors: A. U. Murugananthan, D. Bernardo, P. Tozer, C. T. Tee, E. Mann, A. L. Hart, N. Arebi, S. C. Knight, H. O. Al-Hassi
Journal: Gut (2011)

<h3>Introduction</h3> Th1 and Th17 pathways are implicated in Crohn9s disease (CD). In operative resection samples healthy ileum shows high TGFβ levels in patients who develop recurrence, with TGFβ being a known activator of the Th17 response. Other studies in CD show a dominant Th1 cytokine profile, with high levels of IFNγ, which reduce Th17 response and augment Th1 response. The relationship of Th1/Th17 cytokine profiles in postoperative CD has not been examined. The authors aimed to study tissue Th1/Th17 cytokine secretion after in vitro biopsy culture in postoperative CD. <h3>Methods</h3> Colonoscopy was undertaken in postoperative CD patients. Recurrence graded as no/minimal inflammation (Rutgeert Score (RS) ≥1) or progressive inflammation (RS≥2). Ileal biopsies were cultured overnight and cell free supernatants obtained. Supernatant cytokines (IL-2, IL-4, IL-10, IL-17 TNFα, INFg and IL-6) were assessed by flow cytometry using cytometric bead array (Becton Dickinson). Statistical analysis was via unpaired t tests. <h3>Results</h3> Consecutive patients attending endoscopy (n=24, 9M/15F) were identified. Mean age 45.0 years and time from I to C resection was 5.8 years; 5 patients were smokers. Drugs were thiopurines 13, Infliximab 1 and nil 10. Endoscopic severity was i0 n=5, i1 n=6, i2 n=5, i3 n=3, i4 n=5. Mean cytokine concentrations from supernatants are shown in the table 1. Comparison between RS≥1 and ≥2 showed that pro-inflammatory cytokines IL-17a (p&lt;0.02) and IFNγ (p&lt;0.03) were significantly higher in RS i2-i4 neo terminal ileum as compared with those with RS i0-i1. The regulatory cytokine IL-10 was significantly higher in patients with RS≥1 (p&lt;0.038). <h3>Conclusion</h3> Cytokine profiles in those with RS≥2, show higher levels of IL-17a and IFNγ and reduced IL-10 compared to RS≥1. This profile supports a Th17 and Th1 mediated response as one of the early instigators of endoscopic progression in postoperative CD. The authors9 observation is consistent with recent findings of a T cell subset able to produce cytokines involved in both Th1 and Th17 responses. Previous therapies directed at Th1 pathway, for example, anti-IL-12p40 antibody ustekinumab and anti-IFNγ Fontolizumab failed to show significant clinical benefit in CD. Given our findings targeting the Th17 response, for example, with anti-IL-23 antibodies and anti-IL-17 may deliver improved therapeutic outcome.
ECUADOR
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A combination of AT-527, a pan-genotypic guanosine nucleotide prodrug, and daclatasvir was well-tolerated and effective in HCV-infected subjects
Authors: Ounisha Mungur, Elina Berliba, Stefan Bourgeois, Marine Cardona, Alina Jucov, Steven Good, Adel Moussa, Keith Pietropaolo, Xiao-Jian Zhou, Nathaniel Brown, Jean-Pierre Sommadossi
Journal: Journal of Hepatology (2020)
Outcome and cost for stroke patients in academic and community hospitals. Comparison of two groups referred to a regional rehabilitation center
Authors: J. S. Feigenson
Journal: JAMA (1978)

Patients transferred to a regional stroke rehabilitation center from academic hospital centers (124 patients) and from community hospital centers (315 patients) were compared for outcome and cost of treatment. The two groups were matched for Amended International Classification of Disease diagnostic category, age, sex, distribution of weakness, types of neurological deficits, time from the onset of the stroke symptoms to admission to the rehabilitation unit, and the concurrence of major medical problems thought to contribute to cerebrovascular disease. There was no statistically significant difference in functional outcome or length of stay, but acute health care costs for patients treated in community hospitals were about 50% less. (<i>JAMA</i>240:1878-1880, 1978)
Transplantation
Authors: Thomas E. Starzl
Journal: JAMA (1989)

The modern era of whole organ transplantation began in 1962, when drugs were used in combination to treat patients after the technically easy operation of kidney transplantation. The simple kidney model continued for a long time to be the front-runner for advances in the four key elements of clinical transplantation, which could then be applied with minor adaptations for the extrarenal organs. The elements are (1) preservation, (2) tissue matching, (3) immunosuppression, and (4) surgical technique. This orderly progression changed within the last 10 years when the liver emerged as a focal organ of scientific inquiry. For example, the liver has been central in testing better techniques of "slush" preservation. Such methods were introduced more than two decades ago, using a potassium-rich electrolyte solution or a plasmalike solution to cool kidneys by intra-arterial infusion, followed by refrigeration in an ice chest. Cadaveric kidneys could be cooled in this way for
FREE ANTITOXIN IN ILLINOIS.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Electrocardiography
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstracts
Journal: Annals of the Rheumatic Diseases (1953)

The results of administration of corticotrophin to eighteen unselected children suffering from initial attacks of rheumatic fever are reported.Response to treatment was immediate, all clinical signs disappearing in a few days, though the erythrocyte sedimentation rate took considerably longer to return to normal.The optimum dose was about I to 2 i.u./lb.(2-2 to 4-4 i.u./kg.)body weight per day.No severe side-effects were encountered; moon face and mild glycosuria occurred but rapidly cleared up when treatment was stopped.If the dose of corticotrophin was carefully tapered off at the end of the course, all rebound phenomena were avoided.Although in all cases there were initially marked signs of carditis, at the end of a follow-up period ranging from 1 to 11 months only five patients had a mild mitral systolic mur- mur.The author regards this as supporting the view that corticotrophin has a curative, as opposed to a merely suppressive, effect on the rheumatic process.
CONCERNING ATYPICAL TYPHOID FEVER AND PURE TYPHOIDAL SEPTICEMIA.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE DE NOVO ORIGIN OF INFECTIONS.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FRI0582 Open-label, multicenter, dose-escalating phase ii clinical trial on the safety and efficacy of tadekinig alpha in adult onset still's disease
Authors: C Gabay, B Fautrel, J Rech, F Spertini, E Feist, I Koetter, E Hachulla, J Morel, T Schaeverbeke, MA Hamidou, T Martin, B Hellmich, P Lamprecht, H Schultze-Koops, A Sleight, E Schiffrin
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Adult Onset Still9s Disease (AOSD) is a severe systemic autoinflammatory disease. Elevated interleukin (IL)-18 levels correlate with AOSD disease activity, suggesting a central role <h3>Objectives</h3> To examine the safety and efficacy of IL-18 blockade in AOSD with the administration of Tadekinig alpha, a recombinant human IL-18 binding protein <h3>Methods</h3> Patients (Pts) with AOSD according to Yamaguchi criteria were included if they had been previously treated for at least one month with corticosteroids (CS). The pts received either 80 mg (group 1) or 160 mg (group 2) Tadekinig alpha sc three times weekly for 12 weeks. Oral CS and/or conventional DMARDs were allowed at stable dose in combination with Tadekinig alpha. After 3 wks, group 1 pts qualified as non responders (CRP levels did not decrease by ≥50% from baseline values or absence of temperature normalization) could be up-dosed to 160 mg for an additional 12 weeks. The primary endpoint was safety and secondary endpoints included early signs of efficacy <h3>Results</h3> 23 pts were included (10 and 13 in group 1 and group 2, respectively). 6 pts of group 1 were up-dosed to 160 mg. Baseline characteristics and safety and efficacy results are described in Table 1. Most adverse events (AEs) (47) were considered as mild or moderate. Three serious AEs (SAE) were reported including two that were considered not related to the study drug and one possibly related according to the investigator (toxic optic neuropathy). Four premature discontinuations were related to AEs, including 3 cases of injection site reactions and 1 SAE. Systemic response as defined by ≥70% decrease of serum C-reactive protein (CRP) or normalization of CRP and ferritin levels was obtained in 2/10 and 6/13 pts of groups 1 and 2, respectively in the ITT analysis, and in 2/9 and 6/9 pts of groups 1 and 2, respectively, in the PP analysis. <h3>Conclusions</h3> IL-18 blockade by Tadekinig alpha has an acceptable safety profile and is efficacious, in particular at the 160 mg dosage, in patients with refractory AOSD <h3>Disclosure of Interest</h3> C. Gabay Grant/research support from: AB2 Bio, Roche, Pfizer, Consultant for: AB2 Bio, Roche, Pfizer, MSD, BMS, AbbVie, Sanofi, B. Fautrel: None declared, J. Rech: None declared, F. Spertini: None declared, E. Feist: None declared, I. Koetter: None declared, E. Hachulla: None declared, J. Morel: None declared, T. Schaeverbeke: None declared, M. Hamidou: None declared, T. Martin: None declared, B. Hellmich: None declared, P. Lamprecht: None declared, H. Schultze-Koops: None declared, A. Sleight Employee of: Ab2 Bio, E. Schiffrin Employee of: Ab2 Bio
Soluble RANKL and Risk of Nontraumatic Fracture—Reply
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Subdural haematoma and effusion in infancy.
Authors: K. Till
Journal: BMJ (1968)

BRITMattribute to an " abstinence syndrome."In all of the literature which I have been able to survey, and in personal clinical experience, hallucinations have not been seen as a symp- tom of psychostimulant withdrawal.The most generally described symptoms are lethargy, depression, and suicide attempt.I would suspect that these symptoms in the case presented represent the psychologic response of a schizophrenic woman to the withdrawal of a drug on which she is psychic- ally dependent, or a psychic response to hospitalization.Studies have demonstrated the considerable correspondence between very large doses of stimulants over a period of a few days and the development of a paranoid psychosis.'The aetiology of a psychosis which has existed for one and a half years at first observation, developing four and a half years after beginning to take excessive quantities of phenmetrazine, is problematic.This is so especially when that dosage, while excessive, is less than that which may be necessary to cause the acute, drug-induced psychosis.If we may roughly equate 25 mg.phenmetrazine with 5 mg.dexamphetamine, then their patient took the equivalent of 30-40 mg.dex- amphetamine, daily.This is, in my experi- ence, insufficient to cause an acute drug (or sleep deprivation) psychosis.That chronic, moderately high doses of amphetamines can cause a psychosis independent of personality variables has been suggested,2 but not estab- lished.-Iam, etc.,
Fecal Incontinence
Authors: Jane F. Desforges, Robert D. Madoff, J. Graham Williams, Philip F. Caushaj
Journal: New England Journal of Medicine (1992)

FECAL incontinence is personally and socially incapacitating. The stigma is so considerable that many affected patients are unwilling to admit they have fecal incontinence, and physicians are often reluctant even to inquire about it. Fecal incontinence generally affects elderly persons and is particularly prevalent among institutionalized patients.1 However, many young patients are also affected. Data from Great Britain suggest a community prevalence of 4.2 men and 1.7 women per 1000 people who are 15 to 64 years of age, and of 10.9 men and 13.3 women per 1000 people who are 65 or older.2 The prevalence of fecal incontinence ranges . . .
Proteomic analysis of patients with mantle cell lymphoma identifies Hsp90, and other proteins as potential target(s) for drug therapy
Authors: I. M. Ghobrial, D. J. McCormick, S. H. Kaufmann, S. M. Ansell, A. J. Novak, M. J. Stenson, K. L. Krajnik, T. E. Witzig
Journal: Journal of Clinical Oncology (2004)

6530
THE DATE OF THE ASSOCIATION MEETING.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci
Authors: A. L. Bisno
Journal: JAMA (1989)

INFECTIVE endocarditis is a microbial infection of the endocardial surface of the heart. It most frequently involves the heart valves (native or prosthetic) but can occur on the mural endocardium or intravascular foreign bodies such as intracardiac patches and surgically constructed shunts used to repair congenital heart defects. A similar clinical illness, infective endarteritis, develops when there is infection of arteries, including arteriovenous shunts, patent ductus arteriosus, the great vessels, or aneurysms. Depending primarily on the virulence of the infecting microorganism, the clinical course of infective endocarditis may be prolonged and indolent or abrupt and fulminant. Clinical manifestations of infective endocarditis are variable but frequently include fever, cardiac murmurs, cardiac dysfunction, splenomegaly, petechiae, systemic emboli, anemia, and hematuria. Before the era of antibiotics, the disease was uniformly fatal. Organisms that commonly cause infective endocarditis are gram-positive cocci: viridans streptococci, enterococci,<i>Streptococcus bovis</i>, and staphylococci. Together, these organisms account for the